The United Kingdom is witnessing a noticeable surge in interest surrounding mind-altering substances. Beyond the familiar use of psilocybin and LSD, investigators and enthusiasts are increasingly exploring less-charted areas, particularly copyright and the nascent cannabinoid, CBG compound. This burgeoning scene encompasses clinical trials into emo